Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

92.51
-0.7000-0.75%
Pre-market: 93.871.36+1.47%04:01 EDT
Volume:1.10M
Turnover:103.01M
Market Cap:18.33B
PE:-15.55
High:95.31
Open:93.17
Low:92.09
Close:93.21
52wk High:124.49
52wk Low:29.17
Shares:198.17M
Float Shares:179.00M
Volume Ratio:0.53
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.9500
EPS(LYR):-5.9502
ROE:-58.07%
ROA:-30.08%
PB:11.24
PE(LYR):-15.55

Loading ...

BRIEF-Merck No Longer In Talks To Buy Revolution Medicines - WSJ

Reuters
·
Jan 26

Merck no longer in talks to acquire Revolution Medicines, WSJ reports

TIPRANKS
·
Jan 26

Merck No Longer in Talks to Buy Revolution Medicines- WSJ

THOMSON REUTERS
·
Jan 26

Revolution Medicines General Counsel Jeff Cislini Reports Sale of Common Shares

Reuters
·
Jan 24

Revolution Medicines price target raised to $170 from $85 at Stifel

TIPRANKS
·
Jan 22

Revolution Medicines Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

RBC Boosts Price Target on Revolution Medicines to $140 From $77, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 21

Revolution Medicines Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 20

Revolution Medicines Inc : Guggenheim Raises Target Price to $160 From $92

THOMSON REUTERS
·
Jan 20

LifeSci Capital Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Jan 20

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Ionis Pharmaceuticals (IONS) and DENTSPLY SIRONA (XRAY)

TIPRANKS
·
Jan 16

Revolution Medicines Is Maintained at Outperform by Mizuho

Dow Jones
·
Jan 13

Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating

MT Newswires Live
·
Jan 13

Revolution Medicines: Clinical Momentum and Strategic Phase 3 Design Support Buy Rating on RVMD

TIPRANKS
·
Jan 13

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Revolution Medicines (RVMD) and West Pharmaceutical Services (WST)

TIPRANKS
·
Jan 13

Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating

TIPRANKS
·
Jan 13

$30B ‘might not be enough’ for Revolution Medicines, says Stifel

TIPRANKS
·
Jan 13

Revolution Medicines CEO says not commenting on ‘rumors or speculation’

TIPRANKS
·
Jan 13

Revolution Medicines CEO presenting at JPMorgan healthcare conference

TIPRANKS
·
Jan 13

Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers

Reuters
·
Jan 13